HIPEC With Cisplatin, Mitomycin, and Paclitaxel for Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology
Gastric cancer patients whose disease had spread to the peritoneum received infusions of mitomycin, cisplatin and paclitaxel into the peritoneum in a... Read More
Immunotherapy with Anti-PD-1 Effective for Patients with Solid Tumors
A review of 13 clinical trials published in JAMA Oncology found that patients with solid tumors, including stomach tumors, had better survival... Read More
Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting
At ASCO GI, Leap Therapeutics announced that in a trial of DKN-01 in patients with advanced gastric cancer, elevated expression of DKK1... Read More
Association of Acupuncture and Acupressure With Improved Cancer Pain
A review of clinical trials reveals that acupuncture and acupressure help reduce pain and opioid usage in cancer patients.
Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint
The new targeted drug Enhertu showed a promising response rate in a trial of patients with HER2-positive gastric cancer.
Gritstone posts ‘one of the most potent immunogenic-responses for a neoantigen vaccine’
Two patients with gastroesophageal cancer responded well to Gritstone Oncology’s immune-stimulating treatment in an early trial.
Elevar Announces Results from the Angel Trial, A Study of Monotherapy Rivoceranib (Apatinib) In Late-Stage Gastric Cancer Patients
At ESMO 2019, Elevar Therapeutics announced that in a phase 3 trial in gastric cancer patients, rivoceranib did not improve overall survival... Read More
Checkpoint Inhibitor Checks in as Treatment for Advanced Gastric Cancers
Despite mixed results in clinical trials, Keytruda is producing promising survival results in some gastric cancer patients and has promise in combination... Read More
Predictors of Response to Immune Checkpoint Inhibitors in Patients With Advanced Esophagogastric Cancer
In a recent trial of checkpoint inhibitors in gastric or esophageal cancer, patients who reported immune-related side effects also showed longer survival... Read More
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
Leap Therapeutics announced that a combination of its experimental drug DKN-01 and Merck’s Keytruda had a 50% overall response rate in patients... Read More